The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA to weigh easing limits on unproven peptides promoted by RFK Jr. Compounded "semaglutide" is not FDA approved semaglutide.com